Edition:
United States

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

22.42USD
24 Mar 2017
Change (% chg)

-- (--)
Prev Close
$22.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
545,543
52-wk High
$23.36
52-wk Low
$11.42

NKTR.OQ

Chart for NKTR.OQ

About

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $3,448.89
Shares Outstanding(Mil.): 153.83
Dividend: --
Yield (%): --

Financials

  NKTR.OQ Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -1.10 -- --
ROI: -32.87 -2.56 13.01
ROE: -324.73 5.14 14.16

Nektar's opioid painkiller succeeds in key late-stage study

Nektar Therapeutics said its experimental opioid, designed to achieve pain relief without the euphoria that can lead to abuse and addiction, succeeded in a key late-stage study.

Mar 20 2017

UPDATE 2-Nektar's opioid painkiller succeeds in key late-stage study

* Co to discuss next steps with FDA, looks for strategic partner

Mar 20 2017

Nektar's opioid painkiller succeeds in key late-stage study

March 20 Nektar Therapeutics said its experimental opioid, designed to achieve pain relief minus the high levels of euphoria that can lead to abuse and addiction with existing opioids, succeeded in a key late-stage study.

Mar 20 2017

BRIEF-Nektar Therapeutics Q4 loss per share $0.28

* Nektar Therapeutics reports fourth quarter and year-end 2016 financial results

Mar 01 2017

BRIEF-Nektar Therapeutics presents new clinical data from ongoing phase 1 dose-escalation study of NKTR-214

* Nektar Therapeutics presents new clinical data from ongoing phase 1 dose-escalation study of NKTR-214 at the society for immunotherapy of cancer (SITC) 2016 annual meeting

Nov 09 2016

BRIEF-Nektar Therapeutics reports financial results for Q3

* Nektar Therapeutics reports financial results for the third quarter of 2016

Nov 03 2016

BRIEF-Nektar Therapeutics announces public offering of shares

* Nektar therapeutics announces public offering of shares of common stock

Oct 17 2016

Bristol-Myers to test Opdivo with Nektar drug for several cancers

Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.

Sep 27 2016

BRIEF-Bristol-Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration

* Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214

Sep 27 2016

More From Around the Web

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥5,195 -67.00
Eisai Co., Ltd (4523.T) ¥5,928 -114.00
NOF CORPORATION (4403.T) ¥1,174 -16.00
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs2,642.20 +13.85
Novo Nordisk A/S (NOVOb.CO) kr.231.80 +0.20
Pfizer Inc. (PFE.N) $34.00 -0.29
Novartis AG (NOVN.S) CHF73.15 -0.60
Roche Holding Ltd. (ROG.S) CHF250.90 -2.00
Roche Holding Ltd. (RO.S) CHF251.25 -1.25
GlaxoSmithKline plc (GSK.L) 1,662.50 -8.00

Earnings vs. Estimates